CCTG SC.24 Closed to Accrual
Published:Category: Trials
CCTG SC.24, A Randomized Phase II/III Study Comparing Stereotactic Body Radiotherapy (SBRT) versus Conventional Palliative Radiotherapy (CRT) for Patients with Spinal Metastases, has been closed to accrual after the completion of target accrual. Although the trial is closed accrual, treatment and follow up of patients will continue according to the protocol.
The purpose of this study is to find out if SBRT is better than CRT at controlling pain in the spine 3 months after receiving treatment.
Read MoreCCTG IND.225 trial: IND225
Published:Category: Trials
The CCTG IND.225 trial: A Phase II Study of the Assessment of Response to Pembrolizumab in Metastatic Melanoma: CT Texture Analysis as a Predictive Biomarker
has been permanently closed/terminated.
CCTG job opening for a two Study Coordinators and a Research Associate.
Published:Category: Group updates
The CCTG Central Operations and Statistics Office located at Queen's University in Kingston, Ontario has a job opening for a two Study Coordinators and a Research Associate.
Read MoreProtocol training can be submited through the "Centre Admin Menu"
Published:Category: Group updates
Sites may record protocol training in the centre admin menu of the CCTG Site Training Utility (STU). CCTG has offered protocol-specific training for sites since 2012. To continue to be GCP compliant, protocol training has been required for all participants with delegated duties on the trial participants list for all new trials centrally activated after July 1, 2018. This requirement is stated in the Central Activation Letter and Notice of Health Canada Submission
Read MoreRegistration is now open for The Canadian Cancer Research Conference (CCRC)
Published:Category: Group updates
Registration for the 2019 Canadian Cancer Research Conference (CCRC) is now open.The conference will be of interest to cancer researchers, clinicians, and decision-makers across disciplines and at all stages of their career.
Read MoreHealth Canada – Final version of GUI-0100 now available
Published:Category: Group updates
The Guidance Document: Part C, Division 5 of the Food and Drug Regulations “Drugs for Clinical Trials Involving Human Subjects” (GUI-0100) was published online today, August 20, 2019 and can be found on the Health Canada website at:
Read MoreDr. Janet Dancey Key Note Speaker at ICTMC 2019
Published:Category: News
CCTG Director, Dr Janet Dancey will be a Keynote Speaker at the The 5th International Clinical Trials Methodology Conference is being held 6-9th October 2019 in Brighton UK. Dr Dancey will be speaking on the The Evolution of Academic Sponsored Clinical Trials in the 21st Century: Lessons Learned at the Canadian Cancer Trials Group.
Read MoreCCTG Head and Neck Executive Committee is seeking members
Published:Category: Group updates
The Canadian Cancer Trials Group's (CCTG) Head and Neck Executive Committee (HNEC) is currently seeking individuals with interest and experience in head and neck studies to join the HNEC. In broad terms (adapted from the CCTG's Terms of Reference), the roles of the Disease Site Committee (DSC) Executive members are to:
Read More